{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:06:33Z","timestamp":1761541593597,"version":"3.37.3"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T00:00:00Z","timestamp":1616976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Radiation therapy plays an important role in adjuvant treatment for surgically treated cervical cancer with adverse pathological findings. This was the first study to evaluate current practices of adjuvant radiation therapy among centres affiliated with the Korean Radiation Oncology Group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A survey containing specific questions on the demographics in 2019, indications of adjuvant treatment, radiation therapy field, prescription radiation therapy dose, boost radiation therapy and chemotherapy was sent out by e-mail to 93 centres.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The overall response rate was 62.4%. Regarding radiation therapy techniques, intensity-modulated radiation therapy was adopted in most institutions (41\/58, 70.7%). Various risk group criteria were selected for adjuvant radiation therapy and concurrent chemoradiation therapy. One or two risk factors among tumour size, depth of invasion and lymphovascular invasion were considered for adjuvant radiation therapy by 20.7 and 60.3% of the respondents, respectively. The following criteria for concurrent chemoradiation therapy were considered by 60.3% of the respondents: parametrial extension, positive resection margin or lymph node metastasis. Various upper borders were preferred for pelvic radiation therapy by the institutions, and a total dose of 50.4\u00a0Gy in 28 fractions was the most prescribed dose scheme (37\/58, 63.8%). Lymph node bed boost radiation therapy and vaginal cuff brachytherapy were considered for selected patients by 22.4% (13\/58) and 60.3% (35\/58) of the institutions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This survey demonstrated the practice patterns of adjuvant treatment that are prevalent in the field of radiation oncology among members of the Korean Radiation Oncology Group. These findings warrant further consensus on radiation therapy guidelines in the context of adjuvant treatment for cervical cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyab035","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T02:07:26Z","timestamp":1616724446000},"page":"1107-1113","source":"Crossref","is-referenced-by-count":3,"title":["Adjuvant radiotherapy for cervical cancer in South Korea: a radiation oncology survey of the Korean Radiation Oncology Group (KROG 20-06)"],"prefix":"10.1093","volume":"51","author":[{"given":"Nalee","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4742-2772","authenticated-orcid":false,"given":"Won","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"key":"2021070819370412200_ref1","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.3802\/jgo.2017.28.e22","article-title":"Practice guidelines for management of cervical cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement","volume":"28","author":"Lim","year":"2017","journal-title":"J Gynecol Oncol"},{"key":"2021070819370412200_ref2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.prro.2020.04.002","article-title":"Radiation therapy for cervical cancer: executive summary of an ASTRO clinical practice guideline","volume":"10","author":"Chino","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"2021070819370412200_ref3","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00428-018-2362-9","article-title":"The European Society of Gynaecological Oncology\/European Society for Radiotherapy and Oncology\/European Society of Pathology guidelines for the management of patients with cervical cancer","volume":"472","author":"Cibula","year":"2018","journal-title":"Virchows Arch"},{"key":"2021070819370412200_ref4","doi-asserted-by":"crossref","first-page":"iv72","DOI":"10.1093\/annonc\/mdx220","article-title":"Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Marth","year":"2017","journal-title":"Ann Oncol"},{"key":"2021070819370412200_ref5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1006\/gyno.1999.5387","article-title":"A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic oncology group study","volume":"73","author":"Sedlis","year":"1999","journal-title":"Gynecol Oncol"},{"key":"2021070819370412200_ref6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijrobp.2005.10.019","article-title":"A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study","volume":"65","author":"Rotman","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021070819370412200_ref7","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2000.18.8.1606","article-title":"Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix","volume":"18","author":"Peters","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021070819370412200_ref8","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJM199904153401502","article-title":"Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer","volume":"340","author":"Rose","year":"1999","journal-title":"N Engl J Med"},{"key":"2021070819370412200_ref9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3857\/roj.2019.00577","article-title":"Recent trends in intensity-modulated radiation therapy use in Korea","volume":"37","author":"Huh","year":"2019","journal-title":"Radiat Oncol J"},{"key":"2021070819370412200_ref10","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO.2017.77.4273","article-title":"Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG oncology-RTOG 1203","volume":"36","author":"Klopp","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021070819370412200_ref11","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1200\/JCO.19.02381","article-title":"Improvement in patient-reported outcomes with intensity-modulated radiotherapy (RT) compared with standard RT: a report from the NRG oncology RTOG 1203 study","volume":"38","author":"Yeung","year":"2020","journal-title":"J Clin Oncol"},{"key":"2021070819370412200_ref12","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.3802\/jgo.2016.27.e29","article-title":"Practice patterns of adjuvant therapy for intermediate\/high recurrence risk cervical cancer patients in Japan","volume":"27","author":"Ikeda","year":"2016","journal-title":"J Gynecol Oncol"},{"key":"2021070819370412200_ref13","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/jrr\/rraa004","article-title":"Clinical experience of pelvic radiotherapy or chemoradiotherapy for postoperative uterine cervical cancer using intensity-modulated radiation therapy","volume":"61","author":"Yamamoto","year":"2020","journal-title":"J Radiat Res"},{"key":"2021070819370412200_ref14","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/jrr\/rrz041","article-title":"Postoperative pelvic intensity-modulated radiation therapy reduced the incidence of late gastrointestinal complications for uterine cervical cancer patients","volume":"60","author":"Tsuchida","year":"2019","journal-title":"J Radiat Res"},{"key":"2021070819370412200_ref15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3857\/roj.2018.00500","article-title":"Management for locally advanced cervical cancer: new trends and controversial issues","volume":"36","author":"Cho","year":"2018","journal-title":"Radiat Oncol J"},{"key":"2021070819370412200_ref16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13014-020-01606-3","article-title":"Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial","volume":"15","author":"Huang","year":"2020","journal-title":"Radiat Oncol"},{"key":"2021070819370412200_ref17","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13014-019-1324-y","article-title":"Optimal dose limitation strategy for bone marrow sparing in intensity-modulated radiotherapy of cervical cancer","volume":"14","author":"Bao","year":"2019","journal-title":"Radiat Oncol"},{"key":"2021070819370412200_ref18","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ijrobp.2012.04.044","article-title":"Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies","volume":"85","author":"Liang","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021070819370412200_ref19","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/ijgc-2019-000445","article-title":"Analysis of isolated loco-regional recurrence rate in intermediate risk early cervical cancer after a type C2 radical hysterectomy without adjuvant radiotherapy","volume":"29","author":"Velden","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"2021070819370412200_ref20","doi-asserted-by":"crossref","first-page":"320","DOI":"10.4143\/crt.2019.124","article-title":"Prognostic model for survival and recurrence in patients with early-stage cervical cancer: a Korean Gynecologic oncology group study (KGOG 1028)","volume":"52","author":"Paik","year":"2020","journal-title":"Cancer Res Treat"},{"key":"2021070819370412200_ref21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3857\/roj.2016.01893","article-title":"Clinical outcomes in patients treated with radiotherapy after surgery for cervical cancer","volume":"35","author":"Yang","year":"2017","journal-title":"Radiat Oncol J"},{"key":"2021070819370412200_ref22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ygyno.2020.02.031","article-title":"Significance of the number of high-risk factors in patients with cervical cancer treated with radical hysterectomy and concurrent chemoradiotherapy","volume":"157","author":"Kim","year":"2020","journal-title":"Gynecol Oncol"},{"key":"2021070819370412200_ref23","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ygyno.2018.10.018","article-title":"Surgical treatment of \"intermediate risk\" lymph node negative cervical cancer patients without adjuvant radiotherapy-a retrospective cohort study and review of the literature","volume":"151","author":"Cibula","year":"2018","journal-title":"Gynecol Oncol"},{"key":"2021070819370412200_ref24","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ygyno.2004.11.007","article-title":"Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic oncology group\/southwest oncology group\/radiation therapy oncology group trial","volume":"96","author":"Monk","year":"2005","journal-title":"Gynecol Oncol"},{"key":"2021070819370412200_ref25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ygyno.2007.08.086","article-title":"Extracapsular extension of pelvic lymph node metastases is of prognostic value in carcinoma of the cervix uteri","volume":"108","author":"Horn","year":"2008","journal-title":"Gynecol Oncol"},{"key":"2021070819370412200_ref26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ijrobp.2018.05.076","article-title":"Survival benefit of adjuvant brachytherapy after hysterectomy with positive surgical margins in cervical cancer","volume":"102","author":"Li","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021070819370412200_ref27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.brachy.2011.08.005","article-title":"American brachytherapy society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy","volume":"11","author":"Small","year":"2012","journal-title":"Brachytherapy"},{"key":"2021070819370412200_ref28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/ijgc-2020-001733","article-title":"Role of vaginal brachytherapy boost following adjuvant external beam radiotherapy in cervical cancer: Turkish Society for Radiation Oncology Gynecologic Group study (TROD 04-002)","volume":"31","author":"Gultekin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"2021070819370412200_ref29","doi-asserted-by":"crossref","first-page":"E341","DOI":"10.1016\/j.ijrobp.2019.06.1750","article-title":"The case selection for brachytherapy in cervical cancer patients after radical hysterectomy","volume":"105","author":"Lai","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021070819370412200_ref30","doi-asserted-by":"crossref","first-page":"e8384","DOI":"10.1097\/MD.0000000000008384","article-title":"Comparison of chemoradiotherapy with and without brachytherapy as adjuvant therapy after radical surgery in early-stage cervical cancer with poor prognostic factors: an observational study","volume":"96","author":"Lan","year":"2017","journal-title":"Medicine (Baltimore)"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/7\/1107\/38845302\/hyab035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/7\/1107\/38845302\/hyab035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T03:11:21Z","timestamp":1625800281000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/51\/7\/1107\/6199106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,29]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,3,29]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyab035","relation":{},"ISSN":["1465-3621"],"issn-type":[{"type":"electronic","value":"1465-3621"}],"subject":[],"published-other":{"date-parts":[[2021,7]]},"published":{"date-parts":[[2021,3,29]]}}}